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Detection of Melanoma Micrometastases – the Power of PCR
Sentinel lymph node biopsy has been recently advocated as a way
to determine whether lymph node dissection would be necessary
as part of the surgical treatment of melanoma. This concept is based
on the notion that the ‘‘sentinel lymph node’’, the first lymph node
of the draining site of the primary tumor, is never bypassed in
malignant melanoma. Thus, lack of metastases in the sentinel lymph
node has been considered a good prognostic finding. In this issue,
Lukowsky et al (p. 554) have evaluated this concept by examining
the regional lymph nodes, sentinel and nonsentinel, in 24 patients
with malignant melanoma by histopathology and immunohistochem-
istry, and compared these results for the presence of tyrosinase
mRNA as determined by RT-PCR. Because the tyrosinase gene is
expressed exclusively in melanocytic cells, detection of the corres-
ponding transcripts would signify the presence of metastases in the
tissue. As expected, 10 of 20 patients with histologic evidence of
Type XIII, a Transmembrane Protein in the Epidermis
Collagens comprise a superfamily of proteins, and as many as 20
different mammalian collagens have been studied thus far to the extent
that they have been designated by a Roman numeral. Among these
20 collagens, at least a dozen have been demonstrated in the skin. In
this issue, Peltonen et al (p. 635) have examined the localization of
another collagen, type XIII, which has recently been shown to be a
transmembrane protein. Using a variety of immunologic and molecular
biologic techniques, the authors demonstrate that type XIII collagen
is expressed in the epidermis in various contact sites. Specifically,
colocalization studies suggested that type XIII collagen is not a member
of the desmosome, but is likely to be associated with adherens type
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metastasis in the sentinel lymph node were also positive for tyrosinase
mRNA, as were three additional patients without morphologic
evidence, attesting to the sensitivity of the RT-PCR approach.
Surprisingly, however, in seven patients RT-PCR was clearly positive
for tyrosinase mRNA in nonsentinel lymph nodes, whereas the
sentinel lymph node was negative. Assuming the specificity of the
PCR for tyrosinase, it appears that the sentinel lymph node biopsy
may miss micrometastases that have spread beyond the primary
tumor and somehow bypassed the sentinel lymph node. These
results clearly warrant further studies to validate the concept of
sentinel lymph node biopsy. They also suggest that incorporation
of RT-PCR into the armamentoire to examine regional lymph
nodes in patients with malignant melanoma increases the sensitivity
for detection of metastases
junctions. Previously, another collagen, type XVII collagen, has been
shown to be a keratinocyte gene product, in type 2 transmembrane
orientation and a component of hemidesmosomes. Type XVII collagen
clearly confers stability to the dermal–epidermal basement membrane
zone, as mutations in the corresponding gene (COL17A1) underlie a
non-Herlitz type of junctional epidermolysis bullosa, known as general-
ized atrophic benign EB (GABEB). The functional role of type XIII
collagen within the epidermis is currently unknown, but the authors
speculate that, in analogy with type XVII collagen, aberrations in this
collagen may be associated with heritable and/or acquired blistering
skin diseases.
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Type VII Collagen Mutations Underlie Dystrophic Forms of Epidermolysis Bullosa –
the Evidence is Overwhelming!
The spectacular progress recently made in understanding the molecular
basis of various heritable skin diseases is exemplified by dystrophic
epidermolysis bullosa (DEB). At the beginning of this decade nothing
was known of the specific mutations resulting in various forms of
DEB, and the prevailing notion suggested that somehow the expression
of proteolytic enzymes, primarily collagenase, was altered, resulting
in dissolution of anchoring fibrils and other collagenous structures.
Following the cloning of type VII collagen as the candidate gene for
DEB, a number of reports have detailed specific mutations in COL7A1
in different variants of DEB. In this issue, Whittock et al (p. 673)
compare the efficiency of three different mutation detection strategies,
i.e., protein truncation test, fluorescence chemical cleavage of mismatch,
and conformation sensitive gel electrophoresis, for their sensitivity to
detect mutations in COL7A1 in patients with DEB. The results indicate
that none of the these methods alone is able to detect all putative
mutations, but combined use of these techniques yields an overall
sensitivity of 87%. In fact, the authors were able to detect 147 of 169
mutations in a total of 93 patients with DEB, 57 of the mutations
being previously unreported. These novel mutations, together with
previously published ones, brings the total number of COL7A1
mutations in DEB to over 200. Examination of the mutation database
reveals that the majority of the genetic lesions are family specific with
a few recurrent mutations being detected. There is thus far no evidence
for locus heterogeneity, and the gene for collagenase has been excluded
from DEB locus by genetic linkage analyses. These observations have
diagnostic importance with prognostic implications, and they form the
basis for DNA-based prenatal testing and preimplantation genetic
diagnosis, as well as for gene therapy in the future.
